Kalif Eliyahu Sharon, EVP and Chief Financial Officer of Teva Pharmaceutical Industries (TEVA), has demonstrated a consistent pattern of selling activity in the company’s stock, with no recorded purchases across 25 Form 4 filings since 2024. His transactions, all involving TEVA, total approximately $13.6 million in sales, with the largest single sale occurring on February 26, 2026, when he disposed of shares worth $11.6 million. Earlier sales include a $903,462 transaction on February 28, 2025, and a $1.05 million sale on March 6, 2024. The majority of Sharon’s filings relate to derivative transactions—primarily option exercises (coded "M") and awards (coded "A")—with no associated market purchases.
The absence of buy transactions suggests a one-sided disposition of equity, though the sales appear structured around scheduled vesting events rather than discretionary market timing. Notably, Sharon’s most recent transactions in early March 2026 involved derivative adjustments without monetary value, while his last monetized sale occurred in late February 2026. The pattern aligns with typical executive compensation unwinding, where equity awards are converted to cash, but the lack of offsetting buys underscores a net reduction in his TEVA position over time. The filings do not indicate any trading outside of Teva, reflecting a concentrated exposure to the pharmaceutical company.
AI-assisted summary